GlobeNewswire: Gentium S.p.A. Contains the last 10 of 76 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T14:50:49ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2014/03/05/615979/10071389/en/Gentium-S-p-A-Announces-Decision-to-Voluntarily-Delist-American-Depositary-Shares-from-The-NASDAQ-Global-Market.html?f=22&fvtc=4&fvtv=11831Gentium S.p.A. Announces Decision to Voluntarily Delist American Depositary Shares from The NASDAQ Global Market2014-03-05T19:49:56Z<![CDATA[VILLA GUARDIA (COMO), Italy, March 5, 2014 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT), a Jazz Pharmaceuticals company, today announced that it has notified the NASDAQ Stock Market of its intention to voluntarily delist its American Depositary Shares (ADSs) from The NASDAQ Global Market.]]>https://www.globenewswire.com/news-release/2013/12/19/598376/10062111/en/Jazz-Pharmaceuticals-and-Gentium-S-p-A-Announce-Agreement-for-Jazz-Pharmaceuticals-to-Acquire-Gentium-for-57-00-Per-Share.html?f=22&fvtc=4&fvtv=11831Jazz Pharmaceuticals and Gentium S.p.A. Announce Agreement for Jazz Pharmaceuticals to Acquire Gentium for $57.00 Per Share2013-12-19T21:47:43Z<![CDATA[Transaction would add a significant growth product in the European Union and Rest of World markets, Defitelio™ (defibrotide), a treatment for severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation]]>https://www.globenewswire.com/news-release/2013/12/11/596094/10061138/en/Interim-Results-From-Gentium-s-Treatment-IND-for-Defibrotide-and-Additional-Data-on-Defibrotide-in-the-Prevention-of-Acute-Graft-Versus-Host-Disease-aGvHD-Presented-at-the-American.html?f=22&fvtc=4&fvtv=11831Interim Results From Gentium's Treatment IND for Defibrotide and Additional Data on Defibrotide in the Prevention of Acute Graft Versus Host Disease (aGvHD) Presented at the American Society of Hematology Annual Meeting2013-12-11T12:00:00Z<![CDATA[VILLA GUARDIA (COMO), Italy, Dec. 11, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that additional data on Defibrotide were presented this week at the 55th Annual Meeting and Exposition of the American Society of Hematology at the Ernst N. Morial Convention Center in New Orleans, LA, December 7-10, 2013.]]>https://www.globenewswire.com/news-release/2013/11/26/592496/10059561/en/Data-From-Non-HSCT-VOD-Patients-Treated-With-Defibrotide-and-a-Treatment-IND-Update-to-be-Presented-at-the-American-Society-of-Hematology-2013-Annual-Meeting.html?f=22&fvtc=4&fvtv=11831Data From Non HSCT VOD Patients Treated With Defibrotide and a Treatment IND Update to be Presented at the American Society of Hematology 2013 Annual Meeting2013-11-26T12:00:00Z<![CDATA[VILLA GUARDIA (COMO), Italy, Nov. 26, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that an oral presentation and a poster on Defibrotide will be presented at the 55th Annual Meeting and Exposition of the American Society of Hematology to be held at the Ernst N. Morial Convention Center in New Orleans, LA, December 7-10, 2013.]]>https://www.globenewswire.com/news-release/2013/11/19/590892/10058617/en/Gentium-Receives-EMA-Orphan-Drug-Designation-for-Defibrotide-for-the-Prevention-of-GvHD.html?f=22&fvtc=4&fvtv=11831Gentium Receives EMA Orphan Drug Designation for Defibrotide for the Prevention of GvHD2013-11-19T12:00:00Z<![CDATA[VILLA GUARDIA, Italy, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that the European Commission ("EC") has granted Orphan Drug Designation to Defibrotide for the prevention of Graft versus Host Disease ("GvHD"). The designation follows a positive opinion released by the Committee for Orphan Medicinal Products ("COMP") of the European Medicines Agency ("EMA"), on October 10, 2013.]]>https://www.globenewswire.com/news-release/2013/11/14/589827/10058010/en/Defibrotide-Granted-Orphan-Drug-Status-in-Australia.html?f=22&fvtc=4&fvtv=11831Defibrotide Granted Orphan Drug Status in Australia2013-11-14T12:00:00Z<![CDATA[VILLA GUARDIA (COMO), Italy, Nov. 14, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) and Link Healthcare today announced that Defibrotide has been designated as an Orphan Drug for the Treatment of Hepatic Veno-Occlusive Disease (VOD). The sponsor of Defibrotide is Link Healthcare, Gentium's exclusive distribution partner in Australia.]]>https://www.globenewswire.com/news-release/2013/11/12/588986/10057399/en/Gentium-Announces-Successful-Completion-of-Defibrotide-Phase-1-Study-in-Japan.html?f=22&fvtc=4&fvtv=11831Gentium Announces Successful Completion of Defibrotide Phase 1 Study in Japan2013-11-12T12:00:00Z<![CDATA[
VILLA GUARDIA (COMO), Italy, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that the medical team from the Phase 1 Trial Unit of the Translational Research Center at the National University Corporation, Hamamatsu University School of Medicine ("HUSM"), Fukushima Medical University ("FMU") has successfully completed the phase 1 clinical study to evaluate the Safety and Pharmacokinetics of Defibrotide (DF) in Healthy Adults.]]>https://www.globenewswire.com/news-release/2013/10/31/585322/10054928/en/Gentium-Reports-Third-Quarter-2013-Financial-Results.html?f=22&fvtc=4&fvtv=11831Gentium Reports Third Quarter 2013 Financial Results2013-10-31T10:00:00Z<![CDATA[
VILLA GUARDIA (COMO), Italy, Oct. 31, 2013 (GLOBE NEWSWIRE) -- ]]>https://www.globenewswire.com/news-release/2013/10/28/584020/10054632/en/Gentium-to-Report-Third-Quarter-2013-Financial-Results.html?f=22&fvtc=4&fvtv=11831Gentium to Report Third Quarter 2013 Financial Results2013-10-28T11:45:00Z<![CDATA[Conference Call and Webcast on Thursday October 31, 2013 VILLA GUARDIA (COMO), Italy, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it will report its financial results for the third quarter 2013 on Thursday, October 31, 2013 and will hold a conference call and live webcast at 7:00 a.m. ET / 12:00 p.m. CET.]]>https://www.globenewswire.com/news-release/2013/10/22/582177/10053676/en/Gentium-Receives-Marketing-Authorization-From-the-European-Commission-for-Defitelio-R-Defibrotide.html?f=22&fvtc=4&fvtv=11831Gentium Receives Marketing Authorization From the European Commission for Defitelio(R) (Defibrotide)2013-10-22T10:00:00Z<![CDATA[VILLA GUARDIA, Italy, Oct. 22, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that the European Commission has granted a Marketing Authorization for Defitelio]]>